Allergan to take over Kythera who makes Kybella for the neck.
Here’s an open letter I got from Allergan (the makers of Botox):
June 17, 2015
Dear Aesthetic Provider:
I am delighted to share with you that on June 16, 2015 Allergan and Kythera Biopharmaceuticals reached a definitive agreement under which Allergan will acquire Kythera. Kythera, headquartered in Westlake Village, CA, is focused on the discovery, development and commercialization of novel prescription aesthetic products.
The acquisition of Kythera would immediately enhance Allergan’s facial aesthetics portfolio with the addition of KYBELLA™ (deoxycholic acid) injection, the first and only approved non-surgical treatment for contouring moderate to severe submental fullness commonly referred to as a double chin. KYBELLA™ was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2015.
This combination continues Allergan’s rich history of bringing innovation to you and your patients. KYBELLA™ will join a facial aesthetics offering which includes BOTOX®, JUVÉDERM®, VOLUMA, LATISSE® and SKINMEDICA providing you with a more complete offering of products to your patients. In addition, KYBELLA is a pivotal entry point for expanding the use of facial aesthetic products in men.
We are committed to keeping you informed as the combination of Allergan and KYTHERA progresses and are committed to working with you to ensure a smooth transition. We would expect that this acquisition will be completed by the third quarter of 2015. In the meantime, we will continue to operate as two separate companies and so there are no changes in current practices. Any information you require regarding the KYBELLA™ product or training, please visit mykybella.com or contact your local Kythera representative. More information is available on our website, www.Allergan.com.
If you have any questions or concerns, please contact me at IR-AllerganCommunications@Allergan.com.
President Allergan Medical Aesthetics
Allergan Plc, the maker of wrinkle treatment Botox, agreed to buy Kythera Biopharmaceuticals Inc. for about $2.1 billion to add treatments for double chins and male pattern baldness.
At Surgical Artistry, we hope to have Kybella in our office soon.
Actavis purchased Allergan but is changing their name to Allergan.